Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 2

1(16.7%)

6Total

N/A(5)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07380516Not ApplicableNot Yet Recruiting

Xo-Motion R Exoskeleton in SCI-Adoption Study

Role: collaborator

NCT06948175Not ApplicableEnrolling By Invitation

Abdominal Electrical Stimulation for Bowel Dysfunction in SCI

Role: collaborator

NCT06903416Phase 2Recruiting

Non-Invasive Neuromodulation for Upper Extremity Function in Spinal Cord Injury: A Crossover Trial

Role: collaborator

NCT04726059Not ApplicableRecruiting

Motor & Autonomic Concomitant Health Improvements With Neuromodulation & Exercise Training: An SCI RCT

Role: collaborator

NCT04568928Not ApplicableUnknown

Powered Exoskeleton Combined With Functional Electrical Stimulation in Clinical Practice

Role: collaborator

NCT04977284Not ApplicableUnknown

Noninvasive Neuroprosthesis for Autonomic Recovery After SCI

Role: collaborator

NCT02903472Completed

Gastrointestinal and Urinary Tract Microbiome After SCI

Role: collaborator

All 7 trials loaded